Trials / Completed
CompletedNCT03499106
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers
An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of IW-1973
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Cyclerion Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to evaluate the effect of itraconazole (a potent cytochrome P450 isoenzyme \[CYP\]3A inhibitor) on the pharmacokinetics of IW-1973.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IW-1973 | Oral Tablet |
| DRUG | Itraconazole | Oral Capsule |
Timeline
- Start date
- 2018-04-12
- Primary completion
- 2018-07-06
- Completion
- 2018-07-06
- First posted
- 2018-04-17
- Last updated
- 2019-04-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03499106. Inclusion in this directory is not an endorsement.